Skip Navigation

AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer

Brief Summary

Type:
Prostate

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06855277

Study #:
STUDY00161669

Start Date:
Oct 01, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06855277

View Complete Trial Details & Eligibility at ClinicalTrials.gov